• Nitta K, Wajima R, Tachibana G, Inoue S, Ohigashi T, Kurashima H, Sugiyama K. Predicting Lifetime Transition Risk Of Severe Visual Field Defect Using The Monte Carlo Simulation In Japanese Primary Open-Angle Glaucoma Patients. WGC2017 Helsinki, Finland, June 28- July 1, 2017.

  • Okumura H, Inoue S, Naidoo S, Holmstrom S, Akaza H. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan. ISPOR 22nd Annual International Meeting, Boston, Massachusetts, USA, May 20–24, 2017.

  • Nitta K, Inoue S, Fujiwara R, Daito T, Sugiyama K. Study on the forecast formula of suffering severe vision disability withbroadly defined primary open angle Glaucoma. The 27th Meeting of Japan Glaucoma Society. 17-19 September 2016.

  • Okubo Y, Tsuruta D, Tang A, Inoue S, Itakura H, Hanada T, Otsuki M. Research about gap of treatment goals between doctors’ groups and psoriasis patients’ groups in Japan. The 115th Annual Meeting of the Japanese Dermatological Association. June 3-5, 2016.

  • Yamabe K, Inoue S, Kuwabara H, Kobayashi M. Cost-effectiveness analysis for treatment of parkinson’s disease: A systematic review. ISPOR 19th Annual European Congress, Vienna, Austria. 29 October-2 November 2016.

  • Uda A, Hiroi S, Inoue S, Kuwabara H, Yamabe K, Otake K. Study on Patient-Reported Outcomes in Inflammatory Bowel Disease Treatment: A Systematic Review of the Literature. HTAi2016, Tokyo, Japan. 10-14 May, 2016.

  • Nitta K, Wajima R, Tachibana G, Inoue S, Fujiwara R, Sugiyama K. Analysis of Risk Factors for Visual Field Progression in Open Angle Glaucoma. ARVO2016, Seattle, WA, USA. 1-5 May, 2016.

  • Kobayashi M. The Whole picture of cost-efectiveness evaluation in japan. 3th seminar of the center of pharmacoeconomics and QOL research at Niigata University of health and welfare. Niigata University of health and welfare, Niigata, Japan. 5th Mar, 2016. (in Japanese).

  • Yuasa A, Ii Y, Yamamoto Y, Kitazaki S, Murata T, Saito K, Fujimoto Y. Outcome Research To Investigate The Actual Status of MRSA Infection and Usage of ANTI-MRSA Drugs in Real Clinical Settings in Japan : A Retrospective Database Study. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

  • Ikeda S, Murata TKobayashi M. Role of cost-effectiveness analysis in pricing process of new drug in Japan. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.


Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis

and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA